← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 3,246 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
AAAU
Goldman Sachs Physical Gold ETF
Valuation N/A
Financial Services Risk 45 · Elevated
Price$42.81
Model IV—
P/IV—
Limited data — see page
AACB
Artius II Acquisition Inc.
Valuation N/A
Financial Services
Price$10.59
Model IV—
P/IV—
Limited data — see page
AACBR
Artius II Acquisition Inc.
Valuation N/A
Financial Services
Price$0.00
Model IV—
P/IV—
Limited data — see page
AACBU
Artius II Acquisition Inc.
Valuation N/A
Financial Services
Price$10.70
Model IV—
P/IV—
Limited data — see page
AACG
ATA Creativity Global
Valuation N/A
Consumer Defensive Risk 44 · Elevated
Price$0.86
Model IV—
P/IV—
Market implies +21.7%/yr vs model +4.8% · above model
AACI
Armada Acquisition Corp. III
Valuation N/A
Financial Services
Price$9.99
Model IV—
P/IV—
Limited data — see page
AACIU
Armada Acquisition Corp. III
Valuation N/A
Financial Services
Price$10.14
Model IV—
P/IV—
Limited data — see page
AACIW
Armada Acquisition Corp. III
Valuation N/A
Financial Services
Price$0.31
Model IV—
P/IV—
Limited data — see page
AACO
Abony Acquisition Corp. I
Valuation N/A
Financial Services
Price$9.94
Model IV—
P/IV—
Limited data — see page
AACP
Apogee Acquisition Corp
Valuation N/A
Financial Services
Price$10.00
Model IV—
P/IV—
Limited data — see page
AACPU
Apogee Acquisition Corp
Valuation N/A
Financial Services
Price$10.24
Model IV—
P/IV—
Limited data — see page
AAMI
Acadian Asset Management Inc.
Valuation N/A
Financial Services Risk 61 · High
Price$91.56
Model IV—
P/IV—
Market implies +38.1%/yr vs model +2.0% · above model
AAOI
APPLIED OPTOELECTRONICS, INC.
Valuation N/A
Technology Risk 38 · Moderate
Price$135.63
Model IV—
P/IV—
Market implies +50.7%/yr vs model +21.2% · above model
AAON
AAON, INC.
Valuation N/A
Industrials Risk 56 · Elevated
Price$94.83
Model IV—
P/IV—
Market implies +21.2%/yr vs model +28.2% · below model
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
Valuation N/A
Healthcare Risk 45 · Elevated
Price$19.00
Model IV—
P/IV—
Limited data — see page
AARD
Aardvark Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$7.90
Model IV—
P/IV—
Limited data — see page
AAUC
Allied Gold Corp
Valuation N/A
Unknown Risk 27 · Moderate
Price$22.22
Model IV—
P/IV—
Limited data — see page
ABAT
AMERICAN BATTERY TECHNOLOGY Co
Valuation N/A
Basic Materials Risk 31 · Moderate
Price$2.61
Model IV—
P/IV—
Market implies +58.4%/yr vs model +5.0% · above model
ABCL
AbCellera Biologics Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$6.93
Model IV—
P/IV—
Market implies +98.4%/yr vs model +2.0% · above model
ABEO
ABEONA THERAPEUTICS INC.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$5.99
Model IV—
P/IV—
Market implies +53.8%/yr vs model +18.0% · above model
ABEV
AMBEV S.A.
Valuation N/A
Consumer Defensive Risk 37 · Moderate
Price$2.80
Model IV—
P/IV—
Limited data — see page
ABLVW
Able View Global Inc.
Valuation N/A
Consumer Cyclical Risk 34 · Moderate
Price$0.02
Model IV—
P/IV—
Limited data — see page
ABOS
Acumen Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$2.44
Model IV—
P/IV—
Limited data — see page
ABSI
Absci Corp
Valuation N/A
Industrials Risk 29 · Moderate
Price$9.18
Model IV—
P/IV—
Market implies +114.8%/yr vs model +2.0% · above model
ABUS
Arbutus Biopharma Corp
Valuation N/A
Healthcare Risk 42 · Elevated
Price$4.63
Model IV—
P/IV—
Market implies +82.6%/yr vs model +2.0% · above model
ABVC
ABVC BIOPHARMA, INC.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$0.90
Model IV—
P/IV—
Market implies +60.0%/yr vs model +2.0% · above model
ABVE
Above Food Ingredients Inc.
Valuation N/A
Consumer Defensive
Price$0.11
Model IV—
P/IV—
Limited data — see page
ABVEW
Above Food Ingredients Inc.
Valuation N/A
Consumer Defensive
Price$0.02
Model IV—
P/IV—
Limited data — see page
ABVX
Abivax S.A.
Valuation N/A
Healthcare Risk 52 · Elevated
Price$130.93
Model IV—
P/IV—
Limited data — see page
ACAA
Averin Capital Acquisition Corp.
Valuation N/A
Financial Services
Price$9.99
Model IV—
P/IV—
Limited data — see page
ACAAU
Averin Capital Acquisition Corp.
Valuation N/A
Financial Services
Price$10.07
Model IV—
P/IV—
Limited data — see page
ACAAW
Averin Capital Acquisition Corp.
Valuation N/A
Financial Services
Price$0.80
Model IV—
P/IV—
Limited data — see page
ACB
AURORA CANNABIS INC
Valuation N/A
Healthcare Risk 58 · Elevated
Price$3.49
Model IV—
P/IV—
Limited data — see page
ACET
Adicet Bio, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$8.38
Model IV—
P/IV—
Limited data — see page
ACGC
ACP Holdings Acquisition Corp.
Valuation N/A
Financial Services
Price$9.98
Model IV—
P/IV—
Limited data — see page
ACGCU
ACP Holdings Acquisition Corp.
Valuation N/A
Financial Services
Price$10.12
Model IV—
P/IV—
Limited data — see page
ACHR
Archer Aviation Inc.
Valuation N/A
Industrials Risk 40 · Elevated
Price$5.59
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
ACHV
ACHIEVE LIFE SCIENCES, INC.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$6.65
Model IV—
P/IV—
Limited data — see page
ACIU
AC Immune SA
Valuation N/A
Healthcare Risk 32 · Moderate
Price$2.49
Model IV—
P/IV—
Limited data — see page
ACMR
ACM Research, Inc.
Valuation N/A
Industrials Risk 40 · Elevated
Price$83.80
Model IV—
P/IV—
Market implies +33.7%/yr vs model +36.5% · in line
ACOG
Alpha Cognition Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$8.84
Model IV—
P/IV—
Market implies +29.9%/yr vs model +15.0% · above model
ACON
Aclarion, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$2.46
Model IV—
P/IV—
Market implies +31.3%/yr vs model +5.9% · above model
ACP
abrdn Income Credit Strategies Fund
Valuation N/A
Unknown
Price$5.13
Model IV—
P/IV—
Limited data — see page
ACRS
Aclaris Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$5.90
Model IV—
P/IV—
Market implies +37.5%/yr vs model +3.7% · above model
ACRV
Acrivon Therapeutics, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$1.95
Model IV—
P/IV—
Limited data — see page
ACTU
ACTUATE THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.01
Model IV—
P/IV—
Limited data — see page
ACV
Virtus Diversified Income & Convertible Fund
Valuation N/A
Unknown
Price$27.42
Model IV—
P/IV—
Limited data — see page
ACXP
Acurx Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.40
Model IV—
P/IV—
Limited data — see page
ADAC
American Drive Acquisition Co
Valuation N/A
Financial Services
Price$10.10
Model IV—
P/IV—
Limited data — see page
ADACU
American Drive Acquisition Co
Valuation N/A
Financial Services
Price$10.23
Model IV—
P/IV—
Limited data — see page
ADACW
American Drive Acquisition Co
Valuation N/A
Financial Services
Price$0.41
Model IV—
P/IV—
Limited data — see page
ADAG
Adagene Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$4.11
Model IV—
P/IV—
Market implies +48.0%/yr vs model +2.0% · above model
ADCT
ADC Therapeutics SA
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.01
Model IV—
P/IV—
Market implies +10.5%/yr vs model +15.0% · below model
ADGM
Adagio Medical Holdings, Inc.
Valuation N/A
Healthcare Risk 53 · Elevated
Price$0.69
Model IV—
P/IV—
Market implies +45.9%/yr vs model +15.0% · above model
ADIL
ADIAL PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$3.98
Model IV—
P/IV—
Limited data — see page
ADPT
Adaptive Biotechnologies Corp
Valuation N/A
Healthcare Risk 50 · Elevated
Price$24.93
Model IV—
P/IV—
Market implies +41.1%/yr vs model +15.7% · above model
ADSE
Ads-Tec Energy Public Ltd Co
Valuation N/A
Technology Risk 51 · Elevated
Price$11.88
Model IV—
P/IV—
Limited data — see page
ADSEW
Ads-Tec Energy Public Ltd Co
Valuation N/A
Technology Risk 42 · Elevated
Price$0.50
Model IV—
P/IV—
Limited data — see page
ADT
ADT Inc.
Valuation N/A
Technology
Price$7.47
Model IV—
P/IV—
Limited data — see page
ADUR
ADURO CLEAN TECHNOLOGIES INC.
Valuation N/A
Basic Materials Risk 51 · Elevated
Price$16.10
Model IV—
P/IV—
Limited data — see page